Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep
The objectives of this work were to evaluate the in vitro release and in vivo pharmacokinetics and local tolerability of a novel, segmented ethylene-vinyl acetate (EVA) intravaginal ring (IVR) delivering progesterone (P) in drug-naïve ovariectomized female Dorset crossbred sheep. Following preparation and assessment of in vitro release of P, animals were randomized into one of six treatment groups: group 1 Crinone® 8% gel (90 mg); group 2 Prometrium® 200-mg capsules; group 3 placebo IVR; group 4 progesterone (P) IVR 4 mg/day; group 5 P IVR 8 mg/day; or group 6 P IVR 12 mg/day. Crinone 8% gel and Prometrium capsules were administered once daily for 28 days. IVRs were inserted vaginally on day 1 and remained in place through day 14; a new ring was administered on day 15 and was removed at day 28. Animals underwent daily examinations to confirm ring placement, and vaginal irritation was scored from 0 (none) to 4 (severe). Blood samples were taken at scheduled times for pharmacokinetic analysis. Postmortem examinations performed on all IVR groups included vaginal irritation, macroscopic, and microscopic evaluations, including irritation scoring and histopathology. Intravaginal rings were retained over 28 days in all animals. Clinical observations showed no significant abnormal findings in any group. Pharmacokinetic analysis in animals showed sustained release of P over from days 0 through 14 of ring use. Irritation scores and microscopic assessments were consistent with the IVRs being well tolerated. These results will guide future human clinical studies to ultimately develop an IVR for use in women for the prevention of preterm birth.
KeywordsIntravaginal Progesterone Pharmacokinetics Preterm birth
The authors wish to thank QPharma (ring manufacture), MPI Research, a Charles River Company for conducting the animal study, and Pyxant Laboratories for performing the bioanalytical work.
The financial support for this study was provided by Juniper Pharmaceuticals.
- 1.Lawn JE, Gravett MG, Nunes TM, Rubens CE, Stanton C, Group tGR. Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth. 2010;10(1):S1. https://doi.org/10.1186/1471-2393-10-s1-s1.CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Preterm birth. Centers for Disease Control and Prevention. 2016. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm. Accessed 13 August 2018 2018.
- 3.Infant Mortality. Centers for disease control and prevention. 2016. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/infantmortality.htm. Accessed 13 August 2018 2018.
- 4.March of Dimes. Save the children. Born too soon: the global action report on preterm birth. In: Howson C, Kinney M, Lawn J, editors. Geneva: WHO; 2012.Google Scholar
- 9.De Franco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30(5):697–705. https://doi.org/10.1002/uog.5159.CrossRefGoogle Scholar
- 10.Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth with sonographic short cervix: a multicenter, randomized, double-blind,placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38(1):18–31. https://doi.org/10.1002/uog.9017.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Winer N, Bretelle F, Senat M-V, Bohec C, Deruelle P, Perrotin F, et al. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2015;212(4):485.e1-.e10. https://doi.org/10.1016/j.ajog.2014.10.1097.CrossRefPubMedGoogle Scholar
- 12.Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol. 2012;207(5):390.e1-.e8. https://doi.org/10.1016/j.ajog.2012.09.013.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82(3):377–90.Google Scholar
- 20.Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206(2):124.e1-.e19. https://doi.org/10.1016/j.ajog.2011.12.003.CrossRefPubMedGoogle Scholar
- 21.Conde-Agudelo A, Romero R, Nicolaides K, Chaiworapongsa T, O'Brien JM, Cetingoz E, et al. Vaginal progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Gynecol. 2013;208(1):42.e1-.e18. https://doi.org/10.1016/j.ajog.2012.10.877.CrossRefPubMedGoogle Scholar
- 22.Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 2013(7). doi: https://doi.org/10.1002/14651858.CD004947.pub3.
- 25.Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010;82(5):418–27. https://doi.org/10.1016/j.contraception.2010.04.012.CrossRefPubMedGoogle Scholar
- 28.Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception. 2010;82(5):428–34. https://doi.org/10.1016/j.contraception.2010.05.016.CrossRefPubMedGoogle Scholar
- 29.RamaRao S, Clark H, Merkatz R, Sussman H, Sitruk-Ware R. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception. 2013;88(5):591–8. https://doi.org/10.1016/j.contraception.2013.05.004.CrossRefPubMedGoogle Scholar
- 30.Carr SL, Gaffield ME, Dragoman MV, Phillips S. Safety of the progesterone-releasing vaginal ring (PVR) among lactating women: a systematic review. Contraception. 2016;94(3):253–61. https://doi.org/10.1016/j.contraception.2015.04.001.CrossRefPubMedGoogle Scholar
- 31.Dragonis C, Maltaris T, Binder H, Kat M, Mueller A, Cupisti S, et al. Progesterone bioavailability with a progesterone-releasing silicone vaginal ring in IVF candidates. Eur J Med Res. 2007;12:264–7.Google Scholar
- 32.Stadtmauer L, Silverberg KM, Ginsburg ES, Weiss H, Howard B. Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertil Steril. 2013;99(6):1543–9. https://doi.org/10.1016/j.fertnstert.2012.12.052.CrossRefPubMedGoogle Scholar
- 35.Zegers-Hochschild F, Balmaceda JP, Fabres C, Alam V, Mackenna A, Fernández E, et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Hum Reprod. 2000;15(10):2093–7. https://doi.org/10.1093/humrep/15.10.2093.CrossRefPubMedGoogle Scholar
- 36.Romero R, Nicolaides KH, Conde-Agudelo A, O'Brien JM, Cetingoz E, Da Fonseca E, et al. Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol. 2016;48(3):308–17. https://doi.org/10.1002/uog.15953.CrossRefPubMedPubMedCentralGoogle Scholar